Current Management and Unmet Needs for Treating Acute Agitation Associated with Alzheimer's Disease




Objectives


- To understand Agitation in Alzheimer's Disease (AAD) management in assisted living (ALF) and skilled nursing facilities (SNF)
- Describe unmet needs and treatment opportunities





- Agitation associated with Alzheimer's Disease is a neuropsychiatric symptom associated with negative patient, caregiver, and health system outcomes.
- Nonpharmacologic interventions considered first-line treatment
- Many facilities lack time and resources for effective implementation.
- Pharmacologic treatment options are limited, have debatable efficacy, and substantial safety concerns.














Other physical issues: pain / poor sleep / dehydration / constipation / need to use restroom

> Confrontations with other residents; invasion of privacy


Loud noises / shouting / disruptions overstimulation / busy or crowded spaces

Methods

- Health professionals at assisted living facilities (ALF) and skilled nursing facilities (SNF):
 - spent \geq 20% of time managing AAD
 - involved in \geq 40 acute episodes of agitation requiring a prescription in the last 12 months
- 60-minute in-depth web-assisted telephone interview
- Qualitative data collected and transcribed

Mae Kwong, PharmD; Jordan Dawson, PharmD, BCPS, BCCCP; Sonja Hokett, PharmD, MS, MSc **BioXcel Therapeutics, New Haven, CT, USA**

Common Triggers of Acute Agitation Episodes



30% Breakthrough agitation despite scheduled medications



Unmet need exists for FDA approved treatments for agitation in AD

- **20-30%** of AD residents have episodes of acute agitation
- All eventually experience agitation due to the disease process

~60%

of AD pts with agitation receive scheduled medication

~30%*

receiving scheduled medication need Breakthrough rescue medication for agitation

*Caution: small sample size. Percentage provided by n=4

Medication Needs & Concerns:

- Avoids oversedation; reduces fall risk
- Fast onset of action
- Easy administration
- FDA-approved indication for AAD
- Non-controlled substance

Conclusions

- triggers include:

 - Other residents
- ED for care

Limitations

- broader populations.
- of SNFs.



• This research shows an unmet medication need exists for treating Agitation in Alzheimer's Disease in long term care, particularly in ALF and SNF

Desirable treatment characteristics include: Avoids oversedation; reduces fall risk Fast onset of action Ease of administration FDA indication for agitation Non-controlled substance

• Staffing and facility factors are triggers for AAD. Other • Physical discomfort Changes like meal or bath time, sundowning

Agitation can lead to care escalation and transfers to

 Interview results are descriptive and based on a limited number of respondents, so may not be generalizable to

• Because interview questions were asked, response bias may exist, and may not be representative of other ALFs

 Because respondents were identified based on certain quantity of agitation exposures, the results may overrepresent facilities with less agitation.